SPN-817 clinical trials
SPN-817 is named as an intervention in 3 current clinical trials in our USA, Australia and Poland registers. 2 are recruiting patients now. All registered phases are Phase 2. The lead sponsor is Supernus Pharmaceuticals, Inc. The most-studied condition is Focal Onset Seizures.
Patient leaflets for SPN-817
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Trials by status
Trials by phase
Clinical trials of SPN-817
3 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Safety and Tolerability Study of SPN-817 in Adult Patients With Treatment Resistant Epilepsy
NCT05518578 · Epilepsy, Seizures, Epileptic
|
Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc | USA, Australia |
|
RENAISSANCE 2: SPN-817 Phase 2, Double-Blind, Placebo-Controlled Study in Adults With Focal Onset Seizures
NCT06798896 · ClinicalTrials.gov ↗ · Focal Onset Seizures
|
Phase 2 | Recruiting | Supernus Pharmaceuticals, Inc | USA, Poland, Australia |
|
SPN-817 Open-Label Extension Study in Adults With Focal Onset Seizures
NCT07141329 · ClinicalTrials.gov ↗ · Focal Onset Seizures
|
Phase 2 | By invitation | Supernus Pharmaceuticals, Inc | USA, Australia |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Conditions studied with SPN-817
3 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Supernus Pharmaceuticals, Inc | 3 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in USA | 3 | 2 |
| Clinical trials in Australia | 3 | 2 |
| Clinical trials in Poland | 1 | 1 |
A trial with sites in more than one country appears in each of those registers.
Questions about SPN-817 trials
How many clinical trials are testing SPN-817?
3 current trials in our USA, Australia and Poland registers name SPN-817 as a drug or biological intervention, as of the registry sync on 10 November 2026. Completed and withdrawn studies are not counted.
Are SPN-817 trials recruiting patients?
Yes. 2 of the 3 trials are recruiting: 2 with sites in USA, 2 with sites in Australia and 1 with sites in Poland. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors SPN-817 clinical trials?
The lead sponsor is Supernus Pharmaceuticals, Inc. The number in brackets is how many trials each organisation leads.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how SPN-817 works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how SPN-817 works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists SPN-817 (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 10 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.